Drugs · Brain health technique

Anti-Tau Monoclonal Antibodies (Emerging)

Evidence grade: Experimental

Illustration for Anti-Tau Monoclonal Antibodies (Emerging)

Investigational biologics designed to block or clear pathological tau aggregates inside neurons, targeting tau propagation rather than extracellular amyloid. Includes semorinemab, gosuranemab, and tilavonemab currently in late-phase trials.

Practice
Drugs
Principle
Treatment
Tactic
Neuroprotective & Disease-modifying Therapies
Evidence grade
Experimental
Strength of evidence
Low

How to practice Anti-Tau Monoclonal Antibodies (Emerging)

Only accessible through clinical trials. Candidates typically require tau PET or CSF-confirmed pathology. Participation involves repeated infusions and imaging follow-up. No approved clinical use yet; appropriate for those with biomarker-confirmed early Alzheimer’s or MCI in research settings.

The evidence behind Anti-Tau Monoclonal Antibodies (Emerging)

Anti-tau antibodies are experimental lab-made immune proteins designed to grab bits of tau floating between cells. The goal is to stop tau's spread and slow tangle formation. Early human studies show the antibodies reach their target and appear safe so far. Whether they work is unproven, though newer versions look more promising.

Impact on brain health

Tau tangles track more closely with memory and thinking decline than amyloid buildup does. Early studies so far show limited measurable benefit for memory and thinking.

Reviewed by BetterBrain's clinical advisors · Updated November 2026 · Our science

Pair this with other habits from the same practice.

  • Evidence grade: Context Dependent

    Anti-Amyloid Monoclonal Antibodies

    FDA-approved biologic drugs that target beta-amyloid plaques to slow Alzheimer’s progression, including lecanemab (Leqembi®), donanemab (Kisunla™).

    Medium effort

  • Evidence grade: Context Dependent

    Antihypertensives

    Medications that lower blood pressure to protect vascular and brain health, including ACE inhibitors (lisinopril, enalapril), ARBs (losartan, valsartan), calcium channel blockers…

    Low effort · High cost

  • Evidence grade: Context Dependent

    GLP-1 Receptor Agonists

    A class of injectable or oral medications that mimic the hormone glucagon-like peptide-1 (GLP-1) to improve insulin sensitivity, suppress appetite, and reduce inflammation.

See all 20 drugs techniques →

Take control of your brain health

BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.

How BetterBrain worksSee pricing